The purpose of this study is to demonstrate that Lotrafilcon B AIR OPTIX® AQUA sphere modified design lenses are noninferior to Lotrafilcon B AIR OPTIX® AQUA in overall lens fit by comparing the percent of subjects satisfying the "no re-fit" criteria in each treatment group.

Inclusion Criteria:

• Must sign an Informed Consent Document;
• Myopic, wear AIR OPTIX® AQUA lenses in the range of -1.00 to -5.00 diopters (D) in both eyes, and willing to comply with the wearing schedule;
• Manifest cylinder less than or equal to 0.75 D;
• Able to achieve best corrected visual acuity (BCVA) of 20/25 (Snellen) or better in each eye at distance;
• Able to achieve distance visual acuity of at least 20/40 in each eye with habitual and study lenses;
• Wearing spherical AIR OPTIX® AQUA lenses in both eyes for at least 3 months (at least 8 hours per day, at least 5 days per week), wearing the habitual lenses for a minimum of 4 hours prior to the baseline study visit, and achieving an acceptable or optimal fit at baseline visit with habitual lenses in both eyes;
• Other protocol-defined criteria may apply.

Exclusion Criteria:

• Current soft contact lens wearer who regularly sleeps in lenses (1 or more nights per week);
• Any anterior segment infection, inflammation, disease, or abnormality that contraindicates contact lens wear within 6 months prior to enrollment;
• Any use of systemic or ocular medications for which contact lens wear could be contraindicated including any use of topical ocular medications that would require instillation during contact lens wear;
• History of herpetic keratitis;
• History of corneal or refractive surgery or irregular cornea;
• A pathologically dry eye that precludes contact lens wear;
• Monocular (only one eye with functional vision);
• Monovision correction;
• History of intolerance or hypersensitivity to any component of the test articles or associated materials;
• Concurrent participation in a contact lens or contact lens care product clinical trial or within the previous 30 days;
• Eye injury or ocular or intra-ocular surgery within 6 months prior to enrollment;
• Any ocular or systemic medical condition that may, in the opinion of the investigator, preclude safe administration of the study lenses or affect the results of this study;
• Other protocol-defined exclusion criteria may apply.

This analysis population includes all randomized subjects.

Adverse events (AEs) were collected for the duration of the study (June 2014 - July 2014). AEs are reported as pre-treatment and treatment-emergent.

An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users, or other persons, whether or not related to the investigational medical device (test article) and control article.